1. A 58-year-old man with major depressive disorder and well-controlled hypertension on amlodipine 10 mg per day presents to urgent care with a blood pressure of 178/108 mmHg and a headache. His baseline blood pressure over the prior twelve months has consistently been 124/78 to 132/82 mmHg. Three weeks ago his psychiatrist escalated his venlafaxine from 150 mg per day to 300 mg per day due to incomplete antidepressant response. He has been adherent to all medications and denies any new stressors, dietary changes, or new over-the-counter medications. Which explanation best accounts for this clinical presentation, and what is the most appropriate immediate management?
A) The blood pressure elevation reflects a hypertensive urgency caused by amlodipine taper effect; calcium channel blockers produce rebound hypertension when their dose is unchanged but competing vasodilatory mechanisms are lost as venlafaxine's serotonergic activity at 5-HT2A receptors on vascular smooth muscle produces vasoconstriction that overwhelms amlodipine's vasodilatory effect at the new venlafaxine dose
B) The presentation is consistent with serotonin syndrome precipitated by the venlafaxine dose escalation; the blood pressure elevation and headache represent early autonomic instability from serotonin excess, and management requires immediate venlafaxine discontinuation and cyproheptadine administration pending neurological assessment for additional serotonin syndrome features
C) The hypertension most likely reflects a white-coat effect amplified by the antidepressant; venlafaxine at high doses produces anticipatory anxiety that raises baseline sympathetic tone specifically in clinical settings; management is reassurance and home blood pressure monitoring without medication adjustment
D) The blood pressure elevation is a predictable pharmacodynamic consequence of venlafaxine's dose-dependent NET inhibition: at 300 mg per day, NET inhibition is robust and substantially increases sympathetic noradrenergic tone at vascular alpha-1 receptors, raising peripheral vascular resistance; clinical trial data show mean diastolic increases of 4 to 7 mmHg at doses above 300 mg per day with clinically significant hypertension occurring in approximately 3 to 5 percent of patients; management options include dose reduction back to 150 mg, addition of an antihypertensive agent, or switching to an antidepressant with lower cardiovascular burden
E) The elevated blood pressure results from a pharmacokinetic interaction between venlafaxine at 300 mg and amlodipine; at higher venlafaxine doses, CYP3A4 inhibition by venlafaxine becomes clinically significant, reducing amlodipine metabolism and paradoxically raising amlodipine plasma levels to supratherapeutic concentrations that activate baroreceptor reflexes and produce reflex hypertension
ANSWER: D
Rationale:
Option D is correct. This is a classic presentation of SNRI-associated dose-dependent hypertension. Venlafaxine's NET inhibition increases synaptic NE in peripheral sympathetic circuits, raising peripheral vascular resistance through alpha-1 adrenergic receptor activation. This effect is dose-dependent and becomes clinically significant at higher doses: at doses above 300 mg per day, mean diastolic blood pressure increases of 4 to 7 mmHg have been reported in clinical trials, and sustained clinically significant hypertension develops in approximately 3 to 5 percent of patients on therapeutic SNRI doses. The timing — blood pressure elevation appearing three weeks after dose escalation, precisely the interval needed to reach steady-state at the new dose — and the absence of any other explanation make the pharmacodynamic mechanism the most parsimonious explanation. Management options include reducing venlafaxine to the previously tolerated 150 mg dose (accepting incomplete antidepressant response), adding an antihypertensive agent (and optimizing the existing amlodipine or adding a second agent), or switching to an antidepressant with lower NET inhibitory burden such as an SSRI.
Option A: Option A is incorrect. Amlodipine does not produce rebound hypertension when the dose is unchanged; rebound hypertension is a phenomenon associated with centrally acting agents such as clonidine when abruptly discontinued, not with calcium channel blockers; and venlafaxine's serotonergic activity does not produce vasoconstriction through 5-HT2A receptors at a clinically significant level compared to its noradrenergic mechanism.
Option B: Option B is incorrect. Isolated blood pressure elevation and headache without neuromuscular findings — clonus, hyperreflexia, tremor, myoclonus — and without diaphoresis, agitation, or hyperthermia does not constitute serotonin syndrome; serotonin syndrome requires a triad of neuromuscular, autonomic, and mental status features and is not diagnosed on blood pressure elevation alone; venlafaxine dose escalation as a single-agent change does not typically precipitate serotonin syndrome in the absence of a serotonergic combination.
Option C: Option C is incorrect. White-coat effect does not explain a blood pressure reading of 178/108 mmHg in a patient with twelve months of documented normal readings; the magnitude of elevation and its temporal correlation with dose escalation far exceed what white-coat variability accounts for; dismissing this as an anxiety-related clinical visit effect would result in missing a pharmacodynamic adverse effect requiring clinical action.
Option E: Option E is incorrect. Venlafaxine is not a clinically significant CYP3A4 inhibitor at any therapeutic dose; CYP3A4 inhibition is not an established pharmacokinetic property of venlafaxine; amlodipine plasma level elevation through CYP3A4 inhibition by venlafaxine is not a recognized drug interaction, and supratherapeutic amlodipine would be expected to lower blood pressure further, not raise it.
2. A 74-year-old man with Parkinson's disease and newly diagnosed major depressive disorder is referred to a psychiatrist. His neurologist has him on selegiline 5 mg twice daily orally — a dose used in Parkinson's disease that selectively inhibits MAO-B with minimal systemic MAO-A inhibition at this oral dose and formulation. He also takes carbidopa-levodopa and pramipexole. The psychiatrist considers antidepressant options. Which selection and rationale is most clinically sound given the pharmacological constraints of this patient's existing regimen?
A) Mirtazapine is among the safest antidepressant choices for this patient; it operates through alpha-2 adrenergic autoreceptor blockade and postsynaptic serotonin and histamine receptor antagonism without inhibiting SERT or NET, and therefore does not produce the serotonin or norepinephrine reuptake blockade that creates dangerous interactions with MAOIs; its sedative properties may additionally benefit Parkinson's-associated insomnia, and it has no dopaminergic activity that would interfere with levodopa therapy
B) Venlafaxine is the preferred choice because its NET inhibition at doses above 150 mg per day produces central noradrenergic effects that compensate for the dopaminergic depletion underlying Parkinson's motor symptoms, and its SERT inhibition addresses the depression; the low-dose oral selegiline formulation used in Parkinson's disease does not inhibit MAO-A and therefore poses no meaningful serotonin syndrome risk when combined with an SNRI
C) Bupropion is the ideal choice for this patient because its dopaminergic DAT inhibition will augment the therapeutic effect of levodopa on Parkinson's motor symptoms while simultaneously treating depression; the combination of bupropion's dopaminergic activity with levodopa produces a synergistic antiparkinsonian benefit that makes it pharmacologically superior to any serotonergic antidepressant in this setting
D) Duloxetine is safe to use with oral selegiline 5 mg twice daily because at this dose selegiline acts only peripherally on MAO-B in the gut, and duloxetine's central SERT and NET inhibition occurs in brain compartments where peripheral MAO-B inhibition has no access; the blood-brain barrier separates the two drug effects, preventing any meaningful serotonergic interaction
E) An SSRI such as sertraline is the preferred first-line choice in this patient because SSRIs have no NET inhibition and therefore eliminate the noradrenergic interaction risk with selegiline; the serotonin reuptake inhibition of SSRIs is entirely safe with all oral selegiline doses used in Parkinson's disease because serotonin syndrome requires concurrent MAO-A inhibition, which low-dose oral selegiline does not provide
ANSWER: A
Rationale:
Option A is correct. Mirtazapine's mechanism of action — alpha-2 autoreceptor and heteroreceptor blockade, postsynaptic 5-HT2A, 5-HT2C, and 5-HT3 antagonism, and H1 antagonism — does not involve SERT or NET inhibition. Because mirtazapine does not block serotonin or norepinephrine reuptake, it does not accumulate these monoamines in a manner that interacts dangerously with even partial MAO inhibition. Serotonin syndrome requires the combination of increased synaptic serotonin (typically through reuptake blockade) and impaired serotonin degradation (through MAO inhibition); mirtazapine's mechanism bypasses the reuptake step entirely. Additionally, mirtazapine has no dopaminergic activity that would interfere with the carefully titrated levodopa and pramipexole regimen, and its sedative properties may be clinically useful in Parkinson's-associated sleep disturbance.
Option B: Option B is incorrect. While low-dose oral selegiline (5 mg twice daily) does selectively inhibit MAO-B with minimal MAO-A inhibition, the claim that it poses no meaningful serotonin syndrome risk with an SNRI is not pharmacologically safe to apply categorically; the SNRI prescribing information lists all MAOIs as contraindicated regardless of MAO-B selectivity claims; and the risk of MAO-A inhibition at higher brain concentrations of selegiline, or from the amphetamine metabolites of selegiline, makes the combination inadvisable without careful specialist guidance.
Option C: Option C is incorrect. Bupropion's dopaminergic DAT inhibition does not produce a beneficial synergistic antiparkinsonian effect with levodopa in a predictable therapeutic manner; the combination of a dopaminergic antidepressant with dopaminergic antiparkinsonian agents can precipitate psychosis, hallucinations, and dyskinesias in Parkinson's patients who are often susceptible to dopaminergic excess; bupropion is not a recognized adjunct to levodopa therapy.
Option D: Option D is incorrect. The blood-brain barrier does not create a pharmacological compartment that prevents selegiline's CNS effects from interacting with centrally acting antidepressants; selegiline at oral doses does have CNS MAO-B inhibitory effects — that is the basis of its therapeutic mechanism in Parkinson's disease; the claim that peripheral MAO-B inhibition cannot interact with central drug effects misrepresents selegiline's pharmacology.
Option E: Option E is incorrect. SSRIs carry their own serotonin syndrome risk when combined with MAOIs, including selegiline; the SSRI prescribing information lists all MAOI combinations as contraindicated; while low-dose oral selegiline's MAO-B selectivity reduces but does not eliminate serotonin syndrome risk with serotonergic agents, categorically declaring SSRIs safe with all oral selegiline Parkinson's doses overstates the safety evidence and contradicts prescribing guidance.
3. A 49-year-old woman with major depressive disorder and generalized anxiety disorder was started on duloxetine 60 mg per day six weeks ago. She now presents with fatigue, right upper quadrant discomfort, dark urine, and mild jaundice. Laboratory results show alanine aminotransferase (ALT) 8 times the upper limit of normal, aspartate aminotransferase (AST) 6 times the upper limit of normal, and total bilirubin 3.2 mg/dL. She drinks two to three glasses of wine most evenings and had mildly elevated liver enzymes on a pre-treatment panel that were attributed to alcohol use. She denies use of acetaminophen, herbal supplements, or new medications. Which action and explanation is most appropriate?
A) Continue duloxetine at the current dose and recheck liver enzymes in four weeks; transaminase elevations of this magnitude are expected during the first eight weeks of duloxetine therapy as the liver adapts to the new metabolic load, and the clinical picture represents a transient hepatic adaptation response rather than drug-induced liver injury
B) Reduce the duloxetine dose to 30 mg per day and add ursodeoxycholic acid to support hepatic recovery; dose reduction is the first-line response to duloxetine-associated transaminase elevation and is sufficient to reverse drug-induced hepatocellular injury in patients without pre-existing liver disease
C) Discontinue duloxetine immediately; this clinical and laboratory picture is consistent with duloxetine-induced hepatocellular injury — a recognized adverse effect associated with the drug — and two specific risk factors that were present at initiation and should have precluded prescribing were active alcohol use and pre-existing hepatic dysfunction as evidenced by the baseline enzyme abnormalities; with bilirubin elevation accompanying transaminase elevations of this magnitude (a pattern associated with increased risk of hepatic failure), urgent hepatology referral is appropriate and rechallenge with duloxetine is contraindicated
D) Switch to a higher dose of duloxetine (90 mg per day) and co-prescribe N-acetylcysteine; the liver injury reflects inadequate antioxidant capacity in a patient with alcohol-related hepatic vulnerability, and N-acetylcysteine will restore glutathione reserves while the higher duloxetine dose maintains antidepressant efficacy during hepatic recovery
E) Continue duloxetine and initiate workup for viral hepatitis A, B, and C as the most likely cause of this presentation; antidepressant-induced hepatotoxicity is extremely rare and duloxetine-specific hepatotoxicity has not been reported in the post-marketing literature; the coincidental timing with duloxetine initiation should not distract from investigation of the statistically more probable infectious etiology
ANSWER: C
Rationale:
Option C is correct. This patient has developed a hepatocellular injury pattern — markedly elevated transaminases with bilirubin elevation — temporally consistent with duloxetine initiation. Duloxetine-associated hepatotoxicity is a recognized adverse effect documented in the prescribing information, with cases of hepatic failure including fatalities reported in post-marketing surveillance. Two absolute prescribing precautions were present at initiation and were not heeded: substantial alcohol use (two to three glasses of wine most evenings) and pre-existing hepatic dysfunction (mildly elevated baseline liver enzymes). The prescribing information states duloxetine should be avoided in patients with substantial alcohol use or pre-existing liver disease precisely because of hepatotoxicity risk. The current presentation — transaminase elevation greater than five times the upper limit of normal with bilirubin elevation — meets criteria for serious drug-induced liver injury (the Hy's Law pattern, associated with increased risk of hepatic failure). Immediate discontinuation and hepatology referral are the correct responses; rechallenge is contraindicated.
Option A: Option A is incorrect. Transaminase elevations of eight times the upper limit of normal with jaundice and bilirubin elevation do not represent a normal hepatic adaptation to duloxetine; this magnitude of liver injury with bilirubin elevation is a serious adverse drug reaction requiring immediate drug discontinuation, not watchful waiting.
Option B: Option B is incorrect. Dose reduction is not an appropriate response to duloxetine hepatotoxicity of this severity; with bilirubin elevation accompanying significant transaminase rises, continued exposure at any dose risks progressive liver injury; ursodeoxycholic acid has no established role in reversing drug-induced hepatocellular injury from duloxetine.
Option D: Option D is incorrect. Increasing the duloxetine dose in a patient with established drug-induced hepatotoxicity is clinically indefensible; N-acetylcysteine has evidence only for acetaminophen-induced hepatotoxicity and is not a standard treatment for duloxetine hepatotoxicity; this option would worsen the hepatic injury.
Option E: Option E is incorrect. While viral hepatitis must be included in the differential diagnosis, duloxetine-induced hepatotoxicity is a well-documented post-marketing adverse effect and should not be dismissed as extremely rare; the temporal relationship with drug initiation, the pre-existing risk factors that were present, and the absence of other exposures make duloxetine the leading diagnosis; the correct action is to discontinue duloxetine while pursuing the diagnostic workup concurrently, not to continue the drug pending viral serology results.
4. A 36-year-old woman with major depressive disorder has been stable on fluoxetine 40 mg per day for two years. Her psychiatrist decides to switch her to venlafaxine immediate-release 75 mg twice daily for better coverage of her residual fatigue and motivational symptoms. The fluoxetine is stopped on the day venlafaxine is started. Four days later the patient calls reporting electric-shock sensations in her head and limbs, severe nausea, dizziness, profound irritability, and insomnia. The psychiatrist is surprised because she was switched to venlafaxine, not taken off an antidepressant. Which pharmacological explanation best accounts for this unexpected presentation?
A) The patient is experiencing venlafaxine-induced serotonin toxicity; initiating venlafaxine immediately after stopping fluoxetine creates a serotonin excess because fluoxetine's residual SERT-inhibiting norfluoxetine metabolite remains active for several weeks and combines with venlafaxine's SERT inhibition to produce additive transporter blockade sufficient to trigger the FINISH discontinuation syndrome through serotonergic overstimulation
B) Fluoxetine and its active metabolite norfluoxetine have half-lives of one to four days and four to sixteen days respectively, providing a long pharmacokinetic tail that maintained serotonin transporter occupancy — and therefore stable synaptic serotonin levels — throughout the patient's two-year treatment; abruptly stopping fluoxetine on the day of venlafaxine initiation did not transfer this protective long-half-life coverage to venlafaxine, whose immediate-release formulation has a five-hour half-life and achieves therapeutic SERT occupancy only after several days of twice-daily dosing; the four-day gap between fluoxetine's pharmacological departure and venlafaxine's arrival at therapeutic plasma concentrations created a transient functional discontinuation state despite technically never stopping antidepressant treatment
C) The symptoms represent a pharmacodynamic interaction between residual fluoxetine and venlafaxine competing for the same SERT binding sites; when two SERT inhibitors compete for the same transporter simultaneously, allosteric displacement of the longer-established inhibitor produces a rapid rebound in serotonin reuptake that causes acute serotonin depletion and the associated discontinuation-like neurological symptoms
D) The presentation reflects venlafaxine-specific neurotoxicity from the immediate-release formulation; the twice-daily dosing of venlafaxine IR produces peak plasma concentration spikes that activate 5-HT3 receptors in the vestibular nucleus, producing the electric-shock and dizziness symptoms; these symptoms are absent with the extended-release formulation because the lower Cmax does not reach the 5-HT3 activation threshold
E) The patient is experiencing a cholinergic rebound syndrome; fluoxetine's long-term muscarinic receptor desensitization, maintained over two years, reverses rapidly when the drug is stopped; venlafaxine does not share fluoxetine's muscarinic binding profile and therefore cannot sustain the desensitized state, producing a cholinergic rebound that manifests as the described neurological symptoms
ANSWER: B
Rationale:
Option B is correct. This vignette illustrates a pharmacokinetically important and underappreciated mechanism of antidepressant discontinuation syndrome. Fluoxetine's protection against discontinuation symptoms — for itself and for patients transitioning off other short-half-life antidepressants — derives from its exceptionally long pharmacokinetic tail: the parent compound has a half-life of one to four days, and its active metabolite norfluoxetine has a half-life of four to sixteen days. This means fluoxetine provides declining but sustained SERT occupancy for weeks after the last dose, effectively self-tapering its own receptor engagement. When this patient's fluoxetine was stopped on day zero of venlafaxine initiation, norfluoxetine began its gradual multi-week decline. Venlafaxine IR, with its five-hour half-life, requires several days of twice-daily dosing to reach therapeutic steady-state plasma concentrations and meaningful SERT occupancy. The transition created a pharmacokinetic window — roughly days two through five — during which fluoxetine's SERT occupancy had declined substantially but venlafaxine had not yet achieved therapeutic occupancy, producing a functional discontinuation state. The FINISH syndrome symptoms (electric shocks, nausea, dizziness, irritability, insomnia) emerged from this gap. The correct transition strategy would have been to overlap venlafaxine for one to two weeks before stopping fluoxetine, or to allow venlafaxine to reach therapeutic levels before fluoxetine was tapered.
Option A: Option A is incorrect. The symptoms described are discontinuation syndrome, not serotonin toxicity; serotonin syndrome presents with neuromuscular features (clonus, hyperreflexia, tremor) and hyperthermia, not with electric-shock sensations, dizziness, and irritability as isolated features; and serotonin toxicity requires additive serotonergic excess, not a transitional period of reduced SERT occupancy.
Option C: Option C is incorrect. Competitive allosteric displacement of one SERT inhibitor by another does not produce acute serotonin depletion; both fluoxetine and venlafaxine are reversible competitive inhibitors that would produce additive SERT blockade if present simultaneously, not serotonin reuptake rebound from displacement.
Option D: Option D is incorrect. Venlafaxine IR does not activate 5-HT3 receptors in the vestibular nucleus through peak concentration spikes; electric-shock sensations and dizziness in this context are recognized discontinuation syndrome features unrelated to 5-HT3 receptor activation, and this mechanism is pharmacologically fabricated.
Option E: Option E is incorrect. Fluoxetine does not produce clinically significant muscarinic receptor desensitization that, upon cessation, causes a cholinergic rebound syndrome; fluoxetine lacks meaningful anticholinergic activity, and cholinergic rebound is not a recognized mechanism of SSRI discontinuation syndrome.
5. A 31-year-old woman with severe recurrent major depressive disorder has been maintained on venlafaxine 150 mg per day throughout her pregnancy with good psychiatric stability. She is now at 36 weeks gestation and asks her psychiatrist whether she should stop the venlafaxine before delivery to protect her newborn. Her obstetrician has noted that the fetus has been growing normally. Which response is most pharmacologically and clinically accurate regarding the neonatal risk and the appropriate perinatal management approach?
A) Venlafaxine should be tapered and discontinued by 34 weeks gestation in all patients; the drug crosses the placenta freely and accumulates in fetal tissue due to the lower plasma protein concentrations in fetal circulation, reaching concentrations in the fetal brain that are two to three times maternal levels and producing irreversible neonatal neurodevelopmental effects that outweigh any maternal psychiatric benefit in the third trimester
B) Venlafaxine is absolutely contraindicated in the third trimester because NET inhibition in the fetal cardiovascular system produces persistent pulmonary hypertension of the newborn (PPHN) — a life-threatening condition — at a rate sufficient to mandate discontinuation in all pregnant patients regardless of psychiatric severity; maternal depression management must transition to non-pharmacological approaches for the final trimester
C) Venlafaxine can be continued safely through delivery with no additional monitoring of the neonate required; SNRIs do not cross the placenta in clinically significant quantities and fetal drug exposure is negligible at standard therapeutic doses; any neonatal symptoms reported in the literature represent coincidental findings unrelated to maternal SNRI use
D) Venlafaxine should be switched immediately to fluoxetine, which is the only antidepressant with a Category A safety rating in pregnancy; fluoxetine's longer half-life eliminates the possibility of neonatal withdrawal because plasma levels decline too slowly to produce the abrupt monoamine changes that cause neonatal adaptation syndrome
E) Continuing venlafaxine through delivery is generally preferred over abrupt discontinuation in a patient with severe recurrent depression, because the risk of maternal relapse — with its consequences for prenatal care, nutrition, fetal attachment, and postpartum functioning — typically outweighs the neonatal risks; neonates exposed to SNRIs in utero may develop a neonatal adaptation syndrome (NAS) characterized by transient irritability, feeding difficulty, tremor, respiratory irregularity, and hypoglycemia that typically resolves within two weeks without pharmacological treatment; the neonatal team should be informed of maternal SNRI use so they can monitor the neonate appropriately in the immediate postpartum period
ANSWER: E
Rationale:
Option E is correct. The decision to continue venlafaxine through delivery in a patient with severe recurrent major depressive disorder requires individualized risk-benefit analysis. In general, the maternal risk of psychiatric relapse from abrupt antidepressant discontinuation in late pregnancy — including consequences for prenatal care, nutrition, birth planning, and postpartum depression risk — typically outweighs the neonatal risks of in utero SNRI exposure at term. SNRIs, including venlafaxine, do cross the placenta and neonates may develop neonatal adaptation syndrome (also called poor neonatal adaptation syndrome or PNAS): a cluster of transient symptoms including irritability, jitteriness, feeding difficulty, tremor, respiratory irregularity, and hypoglycemia that appear in the first one to three days of life and typically resolve within one to two weeks without pharmacological treatment. This syndrome is distinct from neonatal opioid withdrawal syndrome and is generally mild and self-limiting. The key clinical action is ensuring the neonatal team is informed of maternal venlafaxine use so appropriate monitoring is in place.
Option A: Option A is incorrect. Venlafaxine does not accumulate in fetal tissue at two to three times maternal levels due to reduced fetal protein binding, and the claim of irreversible neonatal neurodevelopmental effects from third-trimester venlafaxine exposure is not supported by current evidence; blanket discontinuation at 34 weeks in all patients without individualized risk assessment is not appropriate clinical practice.
Option B: Option B is incorrect. While persistent pulmonary hypertension of the newborn has been associated with late-pregnancy SSRI exposure in some studies, the association is modest (approximately two to three times the background rate of approximately one to two per thousand), does not constitute an absolute contraindication that mandates discontinuation in all patients, and does not apply uniformly to SNRIs with the certainty implied; a blanket mandate for all pregnant patients is an overstatement of the current evidence.
Option C: Option C is incorrect. SNRIs do cross the placenta in clinically significant quantities, and neonatal adaptation syndrome is a real and recognized phenomenon; dismissing all neonatal symptoms as coincidental is clinically inaccurate and would result in inadequate neonatal monitoring after delivery.
Option D: Option D is incorrect. No antidepressant carries a Category A safety rating in pregnancy — this category applies to agents with controlled human studies showing no fetal risk; all antidepressants are Category C or were unclassified under the prior FDA pregnancy category system; and switching to fluoxetine specifically to prevent neonatal withdrawal conflates pharmacokinetic half-life with absence of neonatal adaptation syndrome, which fluoxetine can also produce.
6. A 62-year-old man with major depressive disorder and dysphagia from a prior stroke has been prescribed bupropion XL 300 mg once daily. Unable to swallow large tablets, he has been crushing the tablet and mixing it with applesauce for the past three weeks. He presents to the emergency department after a witnessed generalized tonic-clonic seizure with no prior seizure history. His bupropion dose has not been changed and he has been adherent. A medication review reveals no other seizure-lowering exposures. Which pharmacological explanation is most accurate, and what is the correct management going forward?
A) Crushing the tablet has no pharmacokinetic consequence because bupropion's extended-release mechanism is based on a pH-dependent coating that is unaffected by physical crushing; the seizure resulted from a separate neurological event related to his prior stroke history rather than from any change in bupropion pharmacokinetics
B) Crushing the XL tablet increased bupropion's bioavailability by eliminating first-pass metabolism that normally occurs during slow tablet transit through the gastrointestinal tract; the higher total drug exposure — not the peak concentration — produced cumulative serotonergic toxicity that lowered the seizure threshold over three weeks of daily administration
C) Bupropion XL uses a controlled-release polymer matrix (Contramid technology) that regulates absorption by slowly releasing drug over twelve to twenty-four hours; crushing destroys this matrix and converts the pharmacokinetics to those of an immediate-release preparation, producing a high peak plasma concentration (Cmax) from the entire 300 mg dose being absorbed rapidly — effectively delivering a single 300 mg immediate-release dose, far exceeding the 150 mg per-dose ceiling for the IR formulation; the resulting Cmax spike is the pharmacokinetic basis for his seizure; going forward, bupropion should be discontinued and an alternative antidepressant that is crushable or available in liquid formulation should be selected
D) The seizure resulted from a pharmacodynamic interaction between crushed bupropion particles and oral mucosal nicotinic acetylcholine receptors; direct contact of bupropion powder with buccal mucosa activates nAChRs and produces a localized depolarization wave that propagates to the temporal lobe and triggers a generalized seizure; this route-specific mechanism is eliminated when the tablet is swallowed intact
E) Crushing the XL tablet is safe for bupropion specifically because unlike other extended-release antidepressants, bupropion XL uses an osmotic pump (OROS) delivery system that remains intact after crushing of the outer tablet shell; the seizure is therefore unrelated to the crushing practice and warrants neurological evaluation for a new seizure disorder
ANSWER: C
Rationale:
Option C is correct. Bupropion XL achieves its extended-release profile through a controlled-release polymer matrix that regulates drug dissolution and absorption, releasing the medication slowly over twelve to twenty-four hours and producing a relatively flat concentration-time profile with a substantially lower Cmax than the immediate-release formulation at the same total dose. When the tablet is crushed, the polymer matrix is physically destroyed and the entire 300 mg dose is released and absorbed rapidly — converting the pharmacokinetics to those of a 300 mg immediate-release dose. This is pharmacologically critical: the IR formulation carries a strict per-dose ceiling of 150 mg precisely because single doses above this threshold produce Cmax values associated with disproportionately high seizure risk. The patient was unknowingly taking the pharmacokinetic equivalent of a 300 mg immediate-release dose daily — twice the safe IR single-dose limit — for three weeks before his seizure. The correct management is to discontinue bupropion and select an alternative antidepressant available in a crushable, chewable, or liquid formulation; mirtazapine orally disintegrating tablets or liquid formulations of SSRIs are practical alternatives in dysphagia patients.
Option A: Option A is incorrect. Bupropion XL's extended-release mechanism is polymer matrix-based, not pH-coating-based, and is completely destroyed by physical crushing; attributing the seizure to the prior stroke without acknowledging the pharmacokinetic consequence of crushing is clinically incorrect and would fail to prevent future seizures.
Option B: Option B is incorrect. Crushing does not eliminate first-pass metabolism — first-pass hepatic metabolism occurs after gastrointestinal absorption regardless of tablet formulation; the mechanism of increased seizure risk is elevated Cmax (peak concentration) from rapid absorption of the full dose, not increased bioavailability from reduced first-pass effect.
Option D: Option D is incorrect. Direct activation of buccal mucosal nicotinic acetylcholine receptors by bupropion powder producing a propagating cortical seizure is not an established pharmacological mechanism; bupropion's weak nAChR blocking properties do not produce generalized seizures through this route-specific pathway.
Option E: Option E is incorrect. Bupropion XL does not use an osmotic pump (OROS) delivery system; OROS technology is used in some other extended-release formulations such as methylphenidate ER and certain antihypertensives; bupropion XL uses a polymer matrix that is destroyed by crushing, making the crushing practice directly responsible for the seizure.
7. A 44-year-old woman with major depressive disorder and fibromyalgia has failed two SSRI trials — escitalopram and sertraline — due to inadequate response on both conditions. Her rheumatologist and psychiatrist are now collaborating on a single pharmacological agent that could address both her psychiatric and pain diagnoses. They debate between duloxetine and pregabalin. Which analysis most accurately characterizes the pharmacological basis for the preferred choice?
A) Duloxetine is the preferred single-agent choice for this patient; it carries FDA approval for both major depressive disorder and fibromyalgia, addresses both conditions through its dual SERT and NET inhibition — with the noradrenergic component augmenting descending pain inhibitory pathways in the spinal dorsal horn that underlie its fibromyalgia efficacy — and addresses the documented failure of pure SERT inhibition by adding the noradrenergic mechanism absent in both prior SSRI trials; pregabalin is FDA-approved for fibromyalgia but has no established antidepressant efficacy and would require a separate agent for the psychiatric indication
B) Pregabalin is the preferred choice because its alpha-2-delta subunit calcium channel modulation in the spinal dorsal horn addresses the central sensitization underlying fibromyalgia more effectively than duloxetine's monoaminergic mechanism; pregabalin also has established antidepressant properties through its anxiolytic effects on the limbic system, making it genuinely dual-purpose without requiring SERT or NET inhibition
C) Both agents are equivalent for this patient because fibromyalgia and major depressive disorder share a common pathophysiology of reduced GABAergic inhibitory tone in the central nervous system; both duloxetine and pregabalin restore this inhibitory tone through complementary mechanisms — duloxetine by increasing monoaminergic inhibition and pregabalin by enhancing GABA release — producing equivalent outcomes for both conditions simultaneously
D) Neither duloxetine nor pregabalin is appropriate as monotherapy; the correct approach is to combine an SSRI — which the patient has already failed — with low-dose tricyclic antidepressant (TCA) amitriptyline, which addresses fibromyalgia through sodium channel blockade in peripheral sensory neurons and depression through SERT and NET inhibition; the prior SSRI failures do not preclude re-trialing an SSRI in combination with TCA augmentation
E) Duloxetine is contraindicated in this patient because fibromyalgia is a centrally sensitized pain syndrome driven by substance P excess in the dorsal horn, and duloxetine's NET inhibition increases NE at alpha-1 receptors on dorsal horn interneurons, paradoxically facilitating substance P release and worsening central sensitization; pregabalin is the only approved agent that interrupts this mechanism
ANSWER: A
Rationale:
Option A is correct. Duloxetine is uniquely positioned for this patient because it carries FDA approval for both major depressive disorder and fibromyalgia — the only SNRI with approval for fibromyalgia as a specific indication — and its dual SERT and NET mechanism addresses the documented inadequacy of pure SERT inhibition in both prior SSRI trials. The noradrenergic component — absent in both escitalopram and sertraline — augments descending noradrenergic and serotonergic inhibitory control over spinal nociceptive transmission in the dorsal horn, the central pain-modulatory pathway relevant to fibromyalgia pathophysiology. This represents a mechanistic advance over what the patient has already received. Pregabalin is FDA-approved for fibromyalgia and acts through alpha-2-delta subunit calcium channel modulation to reduce excitatory neurotransmitter release in sensitized dorsal horn circuits — a pharmacologically distinct and effective analgesic mechanism — but it has no established antidepressant efficacy and would require a separate agent for her psychiatric indication, creating the polypharmacy complexity the collaborating physicians wish to avoid.
Option B: Option B is incorrect. Pregabalin does not have established antidepressant efficacy; its anxiolytic properties, while documented in generalized anxiety disorder, do not translate into antidepressant activity sufficient to treat major depressive disorder; characterizing pregabalin as genuinely dual-purpose for depression and fibromyalgia overstates the evidence.
Option C: Option C is incorrect. Fibromyalgia and major depressive disorder do not share a common pathophysiology of reduced GABAergic inhibitory tone as their primary mechanism; duloxetine does not enhance GABA release — it inhibits monoamine reuptake; and pregabalin does not enhance GABA release either — it acts on voltage-gated calcium channel alpha-2-delta subunits, not on GABAergic synaptic transmission directly despite its name.
Option D: Option D is incorrect. The patient has already failed two SSRIs; re-trialing a third SSRI in combination with amitriptyline subjects her to an unnecessary trial of a drug class that has twice failed her for inadequate response; duloxetine's dual mechanism represents a pharmacologically distinct advance from SSRIs, not a variation of them.
Option E: Option E is incorrect. Duloxetine's NET inhibition in the dorsal horn augments descending noradrenergic inhibitory tone, which reduces nociceptive transmission — it does not paradoxically facilitate substance P release; the noradrenergic mechanism in pain modulation involves activation of inhibitory alpha-2 receptors on pain-transmitting neurons and indirect suppression of substance P-containing primary afferent terminals, not alpha-1-mediated facilitation of substance P release.
8. A 67-year-old woman with major depressive disorder has been on mirtazapine 30 mg at bedtime for four months with good antidepressant response and improved sleep. Routine pre-operative ECG for an elective knee replacement shows a QTc interval of 478 ms, up from a baseline of 438 ms documented two years prior. Her other medications are metoprolol, amlodipine, and atorvastatin, none of which have been changed in dose or formulation. Her electrolytes are normal. The anesthesiologist asks whether mirtazapine is responsible for the QTc prolongation. Which pharmacological analysis most accurately addresses this question?
A) Mirtazapine is the definitive cause of the QTc prolongation; its potent H1 receptor antagonism blocks cardiac HERG (human ether-a-go-go related gene) potassium channels in the same manner as first-generation antihistamines, producing dose-dependent QTc prolongation that is expected to increase by 30 to 50 ms at the 30 mg dose; the drug should be discontinued immediately before the elective surgery
B) Mirtazapine is not associated with QTc prolongation because it is a selective receptor antagonist with no ion channel activity; the QTc change from 438 to 478 ms reflects age-related conduction slowing that is common in women over 65 and is unrelated to any medication; no further cardiac evaluation is needed and the surgery should proceed without medication changes
C) The QTc prolongation is caused by a pharmacodynamic interaction between mirtazapine's alpha-2 adrenergic blockade and metoprolol's beta-1 blockade; by simultaneously blocking alpha-2 autoreceptors and beta-1 receptors, the combination produces unopposed alpha-1 adrenergic stimulation of cardiac myocytes that prolongs phase 2 of the cardiac action potential and extends the QTc interval
D) Mirtazapine is not a clinically established cause of significant QTc prolongation; it does not have meaningful hERG potassium channel blocking activity at therapeutic doses and is not listed among antidepressants associated with clinically significant QTc prolongation — in contrast to TCAs, citalopram, and escitalopram; the QTc increase from 438 to 478 ms in this patient warrants clinical attention but should prompt investigation of other contributing factors — including age, female sex (an independent QTc risk factor), the natural variability in QTc measurement, and any unrecognized electrolyte trends — rather than attribution to mirtazapine
E) The QTc prolongation is caused by a pharmacokinetic interaction in which mirtazapine inhibits CYP3A4, reducing amlodipine metabolism and causing amlodipine accumulation; supratherapeutic amlodipine levels block L-type calcium channels in cardiac myocytes, prolonging the plateau phase of the action potential and extending the QTc interval; the correct management is to reduce the amlodipine dose rather than discontinue mirtazapine
ANSWER: D
Rationale:
Option D is correct. Mirtazapine is not a clinically established cause of significant QTc prolongation. Unlike TCAs (which block hERG potassium channels and sodium channels producing significant cardiac toxicity), citalopram (which has dose-dependent QTc prolongation with an FDA warning), and escitalopram (which carries a similar though lesser cardiac effect), mirtazapine's receptor pharmacology — alpha-2 antagonism, postsynaptic 5-HT receptor antagonism, H1 antagonism — does not include meaningful hERG potassium channel blockade at therapeutic doses. It is not included in standard lists of antidepressants associated with clinically significant QTc prolongation. The observed QTc increase from 438 to 478 ms deserves clinical attention because 478 ms approaches the threshold of concern (typically >500 ms for high risk, but >450 ms in women warrants monitoring), but attribution to mirtazapine without investigating other contributors would be pharmacologically unjustified. Female sex is an independent QTc risk factor; age-related conduction changes, measurement variability between different ECG machines and heart rates, and subclinical electrolyte trends should all be considered. The anesthesiologist's question should be answered: mirtazapine is unlikely to be the cause, and discontinuing it pre-operatively risks antidepressant relapse without addressing the actual source of QTc prolongation.
Option A: Option A is incorrect. Mirtazapine does not block hERG potassium channels in the manner of first-generation antihistamines; H1 receptor antagonism and hERG channel blockade are pharmacologically distinct mechanisms; first-generation antihistamines such as diphenhydramine that cause QTc prolongation do so through hERG blockade that is separate from H1 antagonism; mirtazapine's H1 antagonism does not confer hERG blockade.
Option B: Option B is incorrect. While mirtazapine is not a clinically significant cause of QTc prolongation, dismissing the ECG finding entirely as age-related conduction slowing without further assessment is inadequate; a 40 ms increase in QTc over two years in a patient on new medications warrants investigation rather than reassurance.
Option C: Option C is incorrect. Combined alpha-2 blockade and beta-1 blockade does not produce QTc prolongation through unopposed alpha-1 cardiac stimulation; alpha-1 adrenergic stimulation of cardiac myocytes does not prolong phase 2 of the action potential in a manner that extends QTc; this mechanism is pharmacologically fabricated.
Option E: Option E is incorrect. Mirtazapine is not a clinically significant CYP3A4 inhibitor and does not cause amlodipine accumulation through enzyme inhibition; amlodipine, as a calcium channel blocker acting on L-type channels in vascular smooth muscle, does not produce QTc prolongation through cardiac myocyte calcium channel effects at therapeutic concentrations.
9. A 55-year-old man with major depressive disorder maintained on venlafaxine XR 225 mg per day is admitted for elective hip replacement surgery. His venlafaxine is continued perioperatively per his psychiatrist's recommendation. On postoperative day one he is started on patient-controlled analgesia (PCA) with intravenous fentanyl. Within eighteen hours he develops agitation, diaphoresis, tremor, clonus on ankle examination, and mild hyperthermia with a temperature of 38.3°C. The surgical team considers serotonin syndrome. The anesthesiologist notes the patient has received no other serotonergic medications. Which pharmacological mechanism best explains this presentation?
A) Fentanyl produces serotonin syndrome through mu-opioid receptor activation in the raphe nuclei; mu-opioid stimulation of dorsal raphe serotonergic neurons disinhibits 5-HT release into limbic and cortical circuits, and when combined with venlafaxine's SERT blockade, the resulting serotonin accumulation precipitates the syndrome; all mu-opioid agonists carry this risk when combined with SNRIs
B) Fentanyl has weak but clinically relevant serotonin transporter (SERT) inhibitory activity in addition to its primary mu-opioid receptor agonism; when fentanyl is administered at the relatively high cumulative doses used in PCA settings, its SERT inhibition adds to venlafaxine's existing SERT blockade, increasing synaptic serotonin sufficiently to precipitate serotonin syndrome in a patient whose serotonergic tone is already near the toxicity threshold from therapeutic venlafaxine doses
C) The serotonin syndrome is caused by a pharmacokinetic interaction in which fentanyl inhibits CYP3A4, the primary enzyme metabolizing venlafaxine's active metabolite desvenlafaxine; by blocking desvenlafaxine clearance, fentanyl causes its rapid accumulation to toxic plasma concentrations that produce serotonin syndrome through supraphysiological SERT and NET inhibition
D) This presentation represents opioid-induced neurotoxicity rather than serotonin syndrome; fentanyl at PCA doses produces myoclonus, diaphoresis, and agitation through direct opioid receptor-mediated neuroexcitatory effects on GABA-B receptors in the spinal cord; venlafaxine is incidental and the neurotoxicity would have occurred with fentanyl PCA regardless of any concurrent antidepressant
E) The syndrome results from fentanyl's potent norepinephrine reuptake inhibition, which combines with venlafaxine's NET inhibition to produce a supraadditive noradrenergic excess; the clinical picture of agitation, tremor, diaphoresis, and hyperthermia reflects noradrenergic toxicity rather than serotonin syndrome, and management should target noradrenergic excess with alpha-2 agonist clonidine rather than the serotonin antagonist cyproheptadine
ANSWER: B
Rationale:
Option B is correct. Fentanyl possesses weak but pharmacologically real serotonin transporter (SERT) inhibitory activity in addition to its primary mechanism as a mu-opioid receptor agonist. At the analgesic doses used in standard clinical practice, fentanyl's SERT inhibition is generally below the threshold required to cause serotonin toxicity. However, in a patient whose serotonergic tone is already elevated by therapeutic venlafaxine — a potent SERT inhibitor at 225 mg per day — the additive SERT inhibition from the continuous fentanyl PCA administration can push total serotonergic activity above the threshold for serotonin syndrome. This interaction is clinically important and underappreciated: fentanyl is often considered serotonergically inert when in fact it has documented SERT affinity. The neuromuscular features (tremor, clonus), autonomic features (diaphoresis, hyperthermia), and mental status features (agitation) form the diagnostic triad of serotonin syndrome. Management requires discontinuing fentanyl PCA, transitioning to a non-serotonergic analgesic (such as morphine or hydromorphone, which lack significant SERT activity), providing supportive care, and considering cyproheptadine as a 5-HT2A antagonist if symptoms are moderate to severe.
Option A: Option A is incorrect. Mu-opioid receptor stimulation of dorsal raphe serotonergic neurons does not produce clinically significant disinhibition of 5-HT release as a class effect of all mu-opioid agonists; if this were the mechanism, serotonin syndrome would be a common occurrence with all opioids combined with any serotonergic drug — which is not observed clinically; the mechanism specific to fentanyl is its SERT inhibitory activity, not opioid receptor-mediated serotonin disinhibition.
Option C: Option C is incorrect. Fentanyl is not a clinically significant CYP3A4 inhibitor in the pharmacokinetic sense; it is a CYP3A4 substrate (metabolized by CYP3A4) but does not inhibit the enzyme at clinical concentrations sufficiently to cause desvenlafaxine accumulation; the pharmacokinetic mechanism described is not an established drug interaction between fentanyl and venlafaxine.
Option D: Option D is incorrect. The clinical presentation — agitation, diaphoresis, tremor, clonus, and hyperthermia — is the classic triad of serotonin syndrome and is not adequately explained by opioid-induced neurotoxicity; opioid neurotoxicity typically presents with myoclonus and delirium in the context of renal failure and opioid metabolite accumulation (particularly with morphine's morphine-6-glucuronide), which is not the scenario described; and venlafaxine is not incidental to this presentation.
Option E: Option E is incorrect. Fentanyl does not have clinically significant norepinephrine reuptake inhibitory activity; its weak monoamine transporter activity is at SERT, not NET; and the clinical syndrome described — with clonus, a hallmark neuromuscular feature of serotonin toxicity rather than noradrenergic excess — is serotonin syndrome, not a noradrenergic toxidrome.
10. A 22-year-old woman with major depressive disorder and anorexia nervosa (restrictive subtype — she restricts caloric intake severely but does not engage in purging behaviors such as self-induced vomiting or laxative abuse) is referred for antidepressant management. Her current weight is 82% of ideal body weight and she has no history of seizures or electrolyte abnormalities on recent laboratory testing. Her psychiatrist must select an antidepressant that addresses both conditions without introducing unnecessary risk. Which analysis of antidepressant options is most pharmacologically accurate for this patient?
A) Bupropion is the preferred antidepressant in this patient because its noradrenergic and dopaminergic activity will increase energy and motivation — symptoms of depression that are also reinforcing restrictive behaviors — while its known appetite-suppressing effect will paradoxically normalize eating by reducing the preoccupation with food that characterizes anorexia nervosa; the seizure contraindication applies only to the purging subtype of eating disorders due to electrolyte-driven seizure risk, which is absent here
B) Mirtazapine is absolutely contraindicated in this patient because its 5-HT3 antagonism eliminates the nausea signal that currently limits the patient's caloric intake; by removing this physiological brake on eating, mirtazapine will drive caloric overconsumption, rapid weight gain, and refeeding syndrome in a patient whose hepatic and cardiac physiology may not tolerate rapid nutritional rehabilitation
C) Mirtazapine is a pharmacologically rational choice for this patient; its 5-HT2C and H1 receptor antagonism increases appetite and promotes weight gain — effects that are clinically desirable in a patient with anorexia nervosa and below-normal body weight; it also addresses depression through its noradrenergic and serotonergic disinhibition mechanism; bupropion is contraindicated in all eating disorder subtypes regardless of purging status, because anorexia nervosa with restriction is itself listed as a contraindication in bupropion's prescribing information due to the inherent seizure risk associated with the malnutrition and metabolic dysregulation of the disorder, independent of electrolyte abnormalities from purging
D) An SSRI such as fluoxetine is the only antidepressant with both established antidepressant efficacy and a specific FDA approval for anorexia nervosa; bupropion is contraindicated only in the purging subtype; mirtazapine is contraindicated because weight gain in a patient with anorexia nervosa is a treatment goal that should be pursued through nutritional rehabilitation alone, not pharmacologically, as drug-induced weight gain does not address the underlying psychopathology
E) All antidepressants are equally contraindicated in patients with active anorexia nervosa at weights below 85% of ideal body weight because malnutrition reduces hepatic enzyme activity uniformly, making drug metabolism unpredictable and toxic accumulation likely; the safest approach is to defer all antidepressant pharmacotherapy until the patient reaches 90% of ideal body weight through nutritional rehabilitation
ANSWER: C
Rationale:
Option C is correct. This question requires integrating two pharmacological principles: the weight-gaining properties of mirtazapine and the contraindication profile of bupropion in eating disorders. Mirtazapine's 5-HT2C and H1 receptor antagonism produces appetite stimulation and weight gain — adverse effects in most patients but therapeutically aligned with this patient's clinical need for weight restoration alongside antidepressant treatment. Mirtazapine's antidepressant mechanism through alpha-2 autoreceptor blockade and serotonergic disinhibition is independent of SERT inhibition, making it pharmacologically appropriate for this patient. Regarding bupropion: the prescribing information lists eating disorders — both bulimia nervosa and anorexia nervosa — as contraindications, not limited to the purging subtype. The rationale includes the metabolic dysregulation and electrolyte vulnerabilities of malnutrition from restriction, which independently reduce seizure threshold even without purging-related electrolyte loss. The absence of laboratory-documented electrolyte abnormalities does not eliminate the structural seizure risk from malnutrition itself.
Option A: Option A is incorrect. The claim that bupropion's seizure contraindication in eating disorders applies only to the purging subtype is pharmacologically inaccurate; the prescribing information lists eating disorders broadly, including anorexia nervosa, as a contraindication; and bupropion's appetite-suppressing properties are actively harmful in a patient requiring weight restoration, not therapeutically beneficial.
Option B: Option B is incorrect. Mirtazapine is not absolutely contraindicated in anorexia nervosa; refeeding syndrome is a medical complication of rapid nutritional rehabilitation in severely malnourished patients but is not caused by mirtazapine's pharmacological appetite stimulation, which acts gradually through receptor mechanisms rather than producing the rapid caloric influx that precipitates refeeding syndrome; mirtazapine is in fact used clinically in anorexia nervosa for both its weight-promoting and antidepressant properties.
Option D: Option D is incorrect. Fluoxetine has no FDA approval for anorexia nervosa; it does have approval for bulimia nervosa; and restricting weight gain approaches exclusively to nutritional rehabilitation while avoiding pharmacological appetite stimulation in a patient who is depressed and has failed to gain weight through standard care ignores the therapeutic role mirtazapine can play.
Option E: Option E is incorrect. There is no uniform contraindication to all antidepressants in anorexia nervosa below 85% of ideal body weight; malnutrition does reduce hepatic enzyme activity but not to a degree that makes all antidepressant use uniformly toxic and unpredictable; individualized prescribing with appropriate monitoring is the clinical standard, not categorical deferral.
11. A 58-year-old woman with major depressive disorder has been stable on mirtazapine 30 mg at bedtime for eight months, reporting good mood response and mild but acceptable morning sedation that has not interfered with her daily functioning. Her primary care physician prescribes ciprofloxacin 500 mg twice daily for a ten-day course to treat a urinary tract infection. Five days into the antibiotic course, she calls reporting significantly worsened daytime sedation, difficulty waking in the morning, and dizziness when standing. Which pharmacokinetic mechanism explains her symptoms, and how should they be managed?
A) Ciprofloxacin is a bactericidal antibiotic with no CYP enzyme interactions; the symptoms represent an independent adverse effect of ciprofloxacin itself — specifically, ciprofloxacin-induced QTc prolongation is producing the dizziness through orthostatic arrhythmias, and the sedation is a direct antibiotic CNS adverse effect; mirtazapine should be continued unchanged and the ciprofloxacin should be discontinued early given the cardiac risk
B) Ciprofloxacin induces CYP1A2, the enzyme responsible for a major portion of mirtazapine's hepatic metabolism; enzyme induction accelerates mirtazapine clearance, reducing plasma concentrations and producing a functional subtherapeutic state; the increased sedation represents a paradoxical CNS stimulation rebound as mirtazapine H1 blockade is lost; the antibiotic should be completed and mirtazapine dose increased to 45 mg during the course
C) Ciprofloxacin inhibits CYP2D6, one of the enzymes responsible for mirtazapine metabolism; the resulting accumulation of mirtazapine's active demethylated metabolite — which has higher H1 receptor affinity than the parent compound — drives the increased sedation; management requires switching ciprofloxacin to a non-CYP2D6-inhibiting antibiotic such as nitrofurantoin
D) The symptoms represent a pharmacodynamic interaction rather than a pharmacokinetic one; ciprofloxacin blocks GABA-A receptors in the reticular activating system, and when combined with mirtazapine's H1 blockade, the combined inhibition of arousal circuits produces a synergistic sedative effect that does not involve any change in mirtazapine plasma concentrations
E) Ciprofloxacin is a potent inhibitor of CYP1A2, one of the three hepatic cytochrome P450 enzymes responsible for mirtazapine's metabolism; by blocking CYP1A2-mediated clearance, ciprofloxacin causes mirtazapine plasma concentrations to rise, amplifying its H1 receptor antagonism (increased sedation and morning grogginess) and its alpha-1 adrenergic blockade (orthostatic dizziness); management during the antibiotic course includes counseling the patient about the expected transient interaction, advising caution with driving and postural changes, and considering a temporary dose reduction of mirtazapine to 15 mg until ciprofloxacin is completed, after which mirtazapine levels will return to baseline
ANSWER: E
Rationale:
Option E is correct. Ciprofloxacin is a potent CYP1A2 inhibitor — a pharmacokinetic property that is clinically important but frequently overlooked in outpatient prescribing. Mirtazapine is metabolized by CYP1A2, CYP2D6, and CYP3A4; when CYP1A2 is inhibited by ciprofloxacin, mirtazapine clearance is reduced and plasma concentrations rise. The clinical consequences are predictable from mirtazapine's receptor profile: increased H1 antagonism from higher plasma concentrations produces more pronounced sedation and morning grogginess, and increased alpha-1 adrenergic blockade — a property of mirtazapine — produces more orthostatic hypotension, accounting for the dizziness on standing. The interaction is pharmacokinetically driven, time-limited to the ciprofloxacin course, and reversible. Management options include: counseling the patient about the expected transient interaction and advising caution with activities requiring alertness and with rapid positional changes; considering a temporary dose reduction to 15 mg for the ten-day antibiotic course; and advising that mirtazapine levels and symptoms will normalize when ciprofloxacin is completed. This case is the pharmacokinetic mirror image of the T2 Q11 case in which tobacco smoking induced CYP1A2 and reduced duloxetine levels — the same enzyme, now inhibited rather than induced, with the opposite clinical consequence.
Option A: Option A is incorrect. Ciprofloxacin does have significant CYP enzyme interactions — specifically CYP1A2 inhibition — and dismissing it as having no CYP interactions is pharmacologically incorrect; while ciprofloxacin can prolong the QTc interval, the patient's symptoms of worsened sedation and morning grogginess are not consistent with QTc-mediated arrhythmia and are more parsimoniously explained by mirtazapine accumulation.
Option B: Option B is incorrect. Ciprofloxacin inhibits CYP1A2 — it does not induce it; enzyme induction and enzyme inhibition produce opposite pharmacokinetic effects; induction would reduce mirtazapine levels and potentially reduce efficacy, whereas inhibition raises levels and amplifies adverse effects; the option describes the wrong direction of the interaction.
Option C: Option C is incorrect. Ciprofloxacin's primary CYP interaction is CYP1A2 inhibition, not CYP2D6 inhibition; mirtazapine does not produce a pharmacologically active demethylated metabolite with higher H1 affinity — it has no established active metabolites contributing to its clinical effects; this option misidentifies both the enzyme and the metabolite.
Option D: Option D is incorrect. Ciprofloxacin does not block GABA-A receptors in the reticular activating system; it is a fluoroquinolone antibiotic that acts on bacterial topoisomerase II and IV and actually has pro-convulsant properties through weak GABA-A inhibition in some contexts, not sedation-promoting GABA-A blockade; a pharmacodynamic sedative interaction with mirtazapine through GABA-A mechanisms is not an established property of ciprofloxacin.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.